Abstract:After oral administration to rats, compared with amorphous cyclosporine A (CsA) powder, CsA‐loaded mucopenetrating nanoparticles increased bioavailability by 43‐fold and shortened the time to maximum plasma concentration (Tmax), while CsA‐loaded mucoadhesive nanoparticles prolonged Tmax. This study aimed to control the oral absorption of cyclosporine A (CsA) with the use of a mucosal drug delivery system (mDDS). Mucopenetrating nanocarriers (MP/NCs) and mucoadhesive nanocarriers (MA/NCs) were prepared by flash nanoprecipitation employing polystyrene‐block‐poly(ethylene glycol) and polystyrene‐block‐poly(N,N‐dimethyl aminoethyl methacrylate), respectively. Their particle distribution in the rat gastrointestinal tract were visualized by fluorescent imaging. Plasma concentrations were monitored after oral administration of CsA‐loaded MP/NCs (MP/CsA) and MA/NCs (MA/CsA) to rats. MP/NCs and MA/NCs had a particle size below 200 nm and ζ‐potentials of 4 and 40 mV, respectively. The results from in vitro experiments demonstrated mucopenetration of MP/NCs and mucoadhesion of MA/NCs. Confocal laser scanning microscopic images showed diffusion of MP/NCs in the gastrointestinal mucus towards epithelial cells and localization of MA/NCs on the surface of the gastrointestinal mucus layer. In a pH 6.8 solution, rapid and sustained release of CsA were observed for MP/CsA and MA/CsA, respectively. After oral dosing (10 mg‐CsA/kg) to rats, amorphous CsA powder exhibited a time to maximum plasma concentration (Tmax) of 3.4 h, maximum plasma concentration (Cmax) of 0.12 μg/mL, and bioavailability of 0.7%. Compared with amorphous CsA powder, MP/CsA shortened Tmax by 1.1 to 2.3 h and increased the bioavailability by 43‐fold to 30.1%, while MA/CsA prolonged Tmax by 3.4 to 6.8 h with Cmax and bioavailability of 0.65 μg/mL and 11.7%, respectively. These pharmacokinetic behaviors would be explained by their diffusion and release properties modulated by polymeric surface modification. The mDDS approach is a promising strategy for the pharmacokinetic control of orally administered CsA.

In Situ Intestinal Absorption of Cyclosporine A Solid Dispersion in Rats.

Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt.

Enhancement of Dissolution of Cyclosporine A Using Solid Dispersions with Polyoxyethylene (40) Stearate.

Cyclosporin A-loaded poly(ethylene glycol)-b-poly(d,l-lactic acid) micelles: preparation, in vitro and in vivo characterization and transport mechanism across the intestinal barrier.

Enhancing The Bioavailability Of Cyclosporine A Using Solid Dispersion Containing Polyoxyethylene (40) Stearate

Preparation and in Vitro Study of Solid Dispersions of Cyclosporine A

[Preparation of Cyclosporine A Ph Sensitive Nanoparticles and Oral Pharmacokinetics in Rats].

Effects of glycerides on the intestinal absorption of cyclosporine a using the in-situ mesenteric vein cannulated rat model

Preparation and Evaluation of Poly(Ethylene Glycol)–Poly(Lactide) Micelles As Nanocarriers for Oral Delivery of Cyclosporine A

Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration

Ph-Sensitive Nanoparticles for Improving the Oral Bioavailability of Cyclosporine A.

Pharmacokinetics and Enhanced Oral Bioavailability in Beagle Dogs of Cyclosporine A Encapsulated in Glyceryl Monooleate/Poloxamer 407 Cubic Nanoparticles

Enhancement of Oral Bioavailability of Cyclosporine A: Comparison of Various Nanoscale Drug-Delivery Systems.

Effect of Surface Modification on the Uptake of Polylactic Acid Nanoparticles Loading Cyclosporine A by Cells in Vitro and on the Body Distribution in Vivo

Two Novel Freeze-Dried Ph-Sensitive Cyclosporine A Nanoparticles: Preparation, in Vitro Drug Release, and in Vivo Absorption Enhancement Effects

Long-term Studies on the Stability and Oral Bioavailability of Cyclosporine A Nanoparticle Colloid

Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A.

Study on Preparation Conditions for Polylactide Nanoparticles Loaded Cyclosporine A and Its Oral Bioavailability in Rats

Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.

Pharmacokinetic control of orally dosed cyclosporine A with mucosal drug delivery system

Solid Self-Nanoemulsifying Cyclosporine A Pellets Prepared by Fluid-Bed Coating: Stability and Bioavailability Study